aid: chimerix
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/chimerix.png
name: Chimerix
description: >-
  Chimerix, Inc. was a biopharmaceutical company headquartered in Durham, North
  Carolina, focused on developing medicines for serious and life-threatening
  diseases. It is best known for brincidofovir (TEMBEXA), an antiviral approved
  by the U.S. FDA in 2021 as a smallpox medical countermeasure, and for
  dordaviprone (ONC201), an investigational small-molecule therapy for
  H3 K27M-mutant diffuse glioma, a form of brain cancer. Chimerix was a publicly
  traded company (NASDAQ: CMRX) and was acquired by Jazz Pharmaceuticals in 2025,
  primarily for dordaviprone; the chimerix.com domain now redirects to
  jazzpharma.com. As a clinical-stage pharmaceutical company, Chimerix does not
  operate a public developer program or API surface — this profile tracks it as a
  company entity within the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/chimerix/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Oncology
- Antivirals
- Life Sciences
- Clinical Stage
apis: []
common:
- type: DomainSecurity
  url: security/chimerix-domain-security.yml
- type: Website
  url: https://www.chimerix.com
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence